182 related articles for article (PubMed ID: 34773182)
1. Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.
Ren C; Wang Y; Zhang M; Kong D; Ning C; Cheng Y; Bian Y; Sun M; Su S; Wang Y; Zhang Y; Lu Y; Li N; Zhao D; Chen X
Pharm Res; 2021 Nov; 38(11):1847-1862. PubMed ID: 34773182
[TBL] [Abstract][Full Text] [Related]
2. Oral Bioavailability and Mass Balance Studies of a Novel Anti-arrhythmic Agent Sulcardine Sulfate in Sprague-Dawley Rats and Beagle Dogs.
Lu YL; Li SJ; Liu GY; Li XC; Yang D; Jia JY; Zhang MQ; Zheng HC; Yu C; Zhu F; Wang YP
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):453-459. PubMed ID: 27402487
[TBL] [Abstract][Full Text] [Related]
3. Determination of the novel antiarrhythmic drug sulcardine sulfate in human plasma by liquid chromatography tandem mass spectrometry and its application in a clinical pharmacokinetic study.
Jia J; Liu G; Zhang M; Lu Y; Lu C; Liu Y; Zheng H; Wang W; Gui Y; Yu C; Li S; Wang Y
Biomed Chromatogr; 2016 Aug; 30(8):1291-6. PubMed ID: 26715470
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects.
Chen Q; Qian HJ; Wang W; Zhang MQ; Lu DY; Lu C; Jin JM; Hu CY; Liu GY; Jia JY; Zheng HC; Li XN; Yu C; Wang YP; Liu Y
Fundam Clin Pharmacol; 2017 Feb; 31(1):120-125. PubMed ID: 27599871
[TBL] [Abstract][Full Text] [Related]
5. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
[TBL] [Abstract][Full Text] [Related]
6. Multiple Dose Pharmacokinetics and Safety of Sulcardine Sulfate in Healthy Chinese Male Subjects: An Open-Label Phase I Clinical Study.
Wang W; Qian HJ; Xin L; Zhang MQ; Lu DY; Jin JM; Liu GY; Jia JY; Zheng HC; Yu C; Wang YP; Zhu F; Liu Y
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):593-599. PubMed ID: 27550655
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-(3,5-bis(1-pyrrolidylmethyl)-4-hydroxybenzyl)-4-methoxybenzenesulfamide (sulcardine) as a novel anti-arrhythmic agent.
Bai DL; Chen WZ; Bo YX; Dong YL; Kang AL; Sun WK; Wang W; Hu ZL; Wang YP
Acta Pharmacol Sin; 2012 Sep; 33(9):1176-86. PubMed ID: 22922342
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
Lin L; Wright MR; Hop CECA; Wong H
Drug Metab Dispos; 2022 Sep; 50(9):1170-1181. PubMed ID: 35779865
[TBL] [Abstract][Full Text] [Related]
9. Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
Li Z; Gao Y; Yang C; Xiang Y; Zhang W; Zhang T; Su R; Lu C; Zhuang X
Drug Metab Dispos; 2020 Jan; 48(1):41-51. PubMed ID: 31699808
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.
Gao ZW; Zhu YT; Yu MM; Zan B; Liu J; Zhang YF; Chen XY; Li XN; Zhong DF
Acta Pharmacol Sin; 2015 Dec; 36(12):1528-36. PubMed ID: 26592518
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.
Nguyen HQ; Lin J; Kimoto E; Callegari E; Tse S; Obach RS
J Pharm Sci; 2017 Sep; 106(9):2758-2770. PubMed ID: 28412400
[TBL] [Abstract][Full Text] [Related]
12. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
[TBL] [Abstract][Full Text] [Related]
13. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
14. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans.
Kong WM; Sun BB; Wang ZJ; Zheng XK; Zhao KJ; Chen Y; Zhang JX; Liu PH; Zhu L; Xu RJ; Li P; Liu L; Liu XD
Acta Pharmacol Sin; 2020 Jun; 41(6):852-865. PubMed ID: 31969689
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
Peters SA
Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
[TBL] [Abstract][Full Text] [Related]
17. A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.
Lu JT; Cai Y; Chen F; Jia WW; Hu ZY; Zhao YS
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):689-703. PubMed ID: 26254911
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
[TBL] [Abstract][Full Text] [Related]
19. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach.
Ge YX; Zhang Z; Yan JY; Ma ZC; Wang YG; Xiao CR; Zhuang XM; Gao Y
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
